Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00580294 · ClinicalTrials.gov registry record · NA

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

A NA study of Pain, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT00580294 is a NA study of Pain that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 12 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00580294, a NA study of Pain, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients. This study will examine if the switching from one pain medication to another can be done over a 24 hour period. Oxymorphone, the drug being studied, is an FDA approved drug for treatment of severe pain.

Conditions Studied

Interventions

  • DRUG Oxymorphone

Study Locations (1)

New York

  • Icahn School of Medcine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2007-11
Est. Completion 2008-08
Phase NA

What the Registry Record Tells You About NCT00580294

The ClinicalTrials.gov registry entry for NCT00580294 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (96% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Oxymorphone is the first listed.

NCT00580294 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00580294 about?

NCT00580294 is a clinical study titled "A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)". The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients. This study will examine if the switching from one pain medication to another can be done over a 24 hour period. Oxymorpho...

What is the current status of trial NCT00580294?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2007-11. Estimated completion is 2008-08.

What conditions does trial NCT00580294 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00580294?

The interventions under investigation include: Oxymorphone (DRUG).

Who is sponsoring clinical trial NCT00580294?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00580294 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.